JP2016529246A - Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法 - Google Patents

Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法 Download PDF

Info

Publication number
JP2016529246A
JP2016529246A JP2016532263A JP2016532263A JP2016529246A JP 2016529246 A JP2016529246 A JP 2016529246A JP 2016532263 A JP2016532263 A JP 2016532263A JP 2016532263 A JP2016532263 A JP 2016532263A JP 2016529246 A JP2016529246 A JP 2016529246A
Authority
JP
Japan
Prior art keywords
carbon atoms
compound
gene
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016532263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529246A5 (enExample
Inventor
ベルトニ、フランチェスコ
インギラミ、ジョルジョ
Original Assignee
オンコエシックス ゲーエムベーハー
オンコエシックス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコエシックス ゲーエムベーハー, オンコエシックス ゲーエムベーハー filed Critical オンコエシックス ゲーエムベーハー
Publication of JP2016529246A publication Critical patent/JP2016529246A/ja
Publication of JP2016529246A5 publication Critical patent/JP2016529246A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016532263A 2013-08-06 2014-08-06 Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法 Ceased JP2016529246A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361862752P 2013-08-06 2013-08-06
US201361862772P 2013-08-06 2013-08-06
US61/862,752 2013-08-06
US61/862,772 2013-08-06
US201361909703P 2013-11-27 2013-11-27
US61/909,703 2013-11-27
PCT/EP2014/002164 WO2015018521A1 (en) 2013-08-06 2014-08-06 Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor

Publications (2)

Publication Number Publication Date
JP2016529246A true JP2016529246A (ja) 2016-09-23
JP2016529246A5 JP2016529246A5 (enExample) 2017-09-21

Family

ID=51298706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016532263A Ceased JP2016529246A (ja) 2013-08-06 2014-08-06 Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法

Country Status (6)

Country Link
US (1) US20160158246A1 (enExample)
EP (1) EP3030242A1 (enExample)
JP (1) JP2016529246A (enExample)
KR (1) KR20160037201A (enExample)
CN (1) CN105899212A (enExample)
WO (1) WO2015018521A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535671A (ja) * 2016-10-20 2019-12-12 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤
JP2023505849A (ja) * 2019-12-11 2023-02-13 清華大学 腫瘍マーカー及び治療ターゲットとしての長鎖ノンコーディングｒｎａ ｌｅｔｎ
US11679106B2 (en) 2015-04-22 2023-06-20 Celgene Quanticel Research, Inc. Bromodomain inhibitor

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2902030B1 (en) 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
WO2011143660A2 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CN106456653A (zh) 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗
US9968620B2 (en) * 2014-08-19 2018-05-15 Oncoethix Gmbh Methods of treating lymphoma using thienotriazolodiazepine compounds
SG11201703414VA (en) 2014-10-27 2017-05-30 Tensha Therapeutics Inc Bromodomain inhibitors
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
PE20181068A1 (es) * 2015-10-02 2018-07-04 Dana Farber Cancer Inst Inc Terapia de combinacion de inhibidores de bromodominios y bloqueo de puntos de control
EP3490553B1 (en) 2016-07-29 2024-08-28 Oncternal Therapeutics, Inc. Combination comprising an indolinone compound and its use in the treatment of lymphoma
BR112019027473A2 (pt) * 2017-07-04 2020-07-07 Jiangsu Hengrui Medicine Co., Ltd. composição farmacêutica e método para preparar a mesma
CN107759607B (zh) * 2017-11-29 2019-08-23 上海万巷制药有限公司 具有抗肿瘤活性的三氮唑并二氮卓化合物及其制备方法
CN107879989B (zh) * 2017-11-29 2020-01-03 重庆市中药研究院 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法
CN112533620B (zh) * 2018-03-05 2025-03-28 慕尼黑工业大学临床教学中心 通过溶瘤腺病毒和cdk4/6抑制剂的组合治疗肿瘤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095912A1 (fr) * 2000-06-16 2001-12-20 Mitsubishi Pharma Corporation Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
WO2009084693A1 (ja) * 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
JP2013532130A (ja) * 2010-05-14 2013-08-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
JP2013544847A (ja) * 2010-12-02 2013-12-19 コンステレーション・ファーマシューティカルズ・インコーポレイテッド ブロモドメイン阻害剤およびその使用
JP2015531365A (ja) * 2012-09-28 2015-11-02 オンコエシックス エスエー チエノトリアゾロジアゼピン化合物を含む医薬製剤
JP2015531747A (ja) * 2012-06-25 2015-11-05 オンコエシックス・エスア チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2902030B1 (en) * 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
US9249161B2 (en) * 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095912A1 (fr) * 2000-06-16 2001-12-20 Mitsubishi Pharma Corporation Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
WO2009084693A1 (ja) * 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
JP2013532130A (ja) * 2010-05-14 2013-08-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
JP2013544847A (ja) * 2010-12-02 2013-12-19 コンステレーション・ファーマシューティカルズ・インコーポレイテッド ブロモドメイン阻害剤およびその使用
JP2015531747A (ja) * 2012-06-25 2015-11-05 オンコエシックス・エスア チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法
JP2015531365A (ja) * 2012-09-28 2015-11-02 オンコエシックス エスエー チエノトリアゾロジアゼピン化合物を含む医薬製剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 120, JPN6018014690, 2012, pages 1657, ISSN: 0003787179 *
CANCER RESEARCH, vol. Vol.73 Issue8 Supplement, JPN6018014687, April 2013 (2013-04-01), pages 10 - 1158, ISSN: 0003787176 *
EUROPEAN JOURNAL OF CANCER, vol. Vol.48, Supplement 6, JPN6018014694, November 2012 (2012-11-01), pages 163 - 528, ISSN: 0003787177 *
HEMATOLOGICAL ONCOLOGY, vol. Vol.31, Issue S1, JPN6018014689, 17 June 2013 (2013-06-17), pages 134 - 114, ISSN: 0003787178 *
日本臨床 造血器腫瘍学−基礎と臨床の最新研究動向−, vol. Vol.70 増刊号2, JPN6018014691, 20 April 2012 (2012-04-20), pages 497 - 502, ISSN: 0003787180 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679106B2 (en) 2015-04-22 2023-06-20 Celgene Quanticel Research, Inc. Bromodomain inhibitor
JP2019535671A (ja) * 2016-10-20 2019-12-12 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤
JP2022095897A (ja) * 2016-10-20 2022-06-28 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤
JP7129973B2 (ja) 2016-10-20 2022-09-02 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤
JP2023505849A (ja) * 2019-12-11 2023-02-13 清華大学 腫瘍マーカー及び治療ターゲットとしての長鎖ノンコーディングｒｎａ ｌｅｔｎ
JP7406278B2 (ja) 2019-12-11 2023-12-27 清華大学 腫瘍マーカー及び治療ターゲットとしての長鎖ノンコーディングｒｎａ ｌｅｔｎ

Also Published As

Publication number Publication date
WO2015018521A1 (en) 2015-02-12
CN105899212A (zh) 2016-08-24
US20160158246A1 (en) 2016-06-09
EP3030242A1 (en) 2016-06-15
KR20160037201A (ko) 2016-04-05

Similar Documents

Publication Publication Date Title
JP2016529246A (ja) Ｂｅｔブロモドメイン阻害剤を用いるびまん性大細胞型ｂ細胞性リンパ腫（ｄｌｂｃｌ）の治療方法
WO2015018522A1 (en) Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
JP2017529332A (ja) チエノトリアゾロジアゼピン化合物を含む医薬組成物を用いる急性骨髄性白血病又は急性リンパ性白血病の治療方法
JP2017514907A (ja) チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び／又はａｌｋ＋非小細胞肺癌の治療方法
US9956228B2 (en) Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
HK1210434A1 (en) Pharmaceutical formulation containing thienotriazolodiazepine compounds
JP2016538310A (ja) チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法
KR20170002610A (ko) 티에노트리아졸로디아제핀 화합물을 사용한 삼중 음성 유방암의 치료 방법
WO2015169953A1 (en) Method of treating glioma using thienotriazolodiazepine compounds
JP6453877B2 (ja) チエノトリアゾロジアゼピン化合物を含む医薬製剤
JP2017517579A (ja) チエノトリアゾロジアゼピン化合物を用いる非小細胞肺癌及び／又は小細胞肺癌の治療方法
US9820992B2 (en) Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds
US9968620B2 (en) Methods of treating lymphoma using thienotriazolodiazepine compounds
WO2015018523A1 (en) A novel bet-brd inhibitor for treatment of solid tumors
WO2015168587A1 (en) Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181108

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190108

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20190528